
Trial supports immunoglobulin in post-polio patients
Positive results from a Phase II/III clinical trial evaluating Grifols’ intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS) have demonstrated a significant improvement in distance walked compared to placebo. The immunomodulatory properties of IVIG – in this case Flebogamma 5% DIF (immune globulin intravenous [human])… Read More
